# Irinotecan

## Irino IV infusion 100mg/5mL

| 藥物代碼 | IIRI |
| :--- | :--- |
| 適應症 | Refractory colorectal malignancies , 1st line treatment of metastatic colorectal cancer |
| 副作用 | Neutropenia, anemia, thrombocytopenia; acute diarrhoea, sweating, hypersalivation, abdominal cramps, lachrymation, miosis, weakness; nausea, vomiting, alopecia and skin reactions; cardiovascular toxicity.Potentially Fatal: Fatal sepsis due to myelosuppression; severe, chronic diarrhoea |
| 禁忌 | Known hypersensitivity to irinotecan or any component of the formulation. Coadministraton with azole antifungals \(ketoconazole, fluconazole, itraconazole\); patients with hereditary fructose intolerance |
| 藥物保存方式 | 室溫 |
| 用法用量 | IV Refractory colorectal malignancies 125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period. 1st line treatment of metastatic colorectal cancer 125 mg/m2 on days 1,8,15 and 22 of a 6-wk cycle. |
| 肝功能異常 | 需 調 整 劑 量  Bilirubin &gt;ULN to ?2 mg/dL: Consider reducing initial dose by one dose level Bilirubin &gt;2 mg/dL: Use is not recommended |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度在 0.12 - 2.8 mg/mL，室溫安定性維持 12 小時。 3. 監測CBC、肝功能。 4. 注意病人可能出現腹瀉的藥物副作用，尤其是65歲以上的老年人。 若病人注射Irinotecan後發生延遲性腹瀉，應盡快聯絡醫師，給予適當治療。 |

